Zanubrutinib tested for anti-MAG neuropathy, a nerve disease
Tests zanubrutinib in adults with anti-MAG antibody neuropathy, a nerve disorder.
Plain-language title generated from the registry record
Registry title: Zanubritnib and anti-MAG neuropathy
Key facts
- Where
- Genoa, Milan, Padova, Pavia, Rome, Rozzano, Trieste, and Turin, ItalySee the 9 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with anti-MAG antibody neuropathy and an IgM monoclonal protein, who will take zanubrutinib for 12 months.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Anti-MAG antibody polyneuropathy linked to an IgM monoclonal protein (MGUS, Waldenstrom macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia or low-grade lymphoma).
- Earlier treatment
- No earlier treatment with BTK inhibitors. No use of strong or moderate CYP3A inducers within 14 days before the first dose.
- Biomarker or test result
- Anti-MAG antibodies with a titer of 7.000 BTU or more.
Main reasons for not taking part
- Earlier treatment with BTK inhibitors
- Aggressive non-Hodgkin lymphoma or IgM multiple myeloma
- Moderate or severe motor nerve axonal damage
- ECOG above 3
- Creatinine clearance below 30 mL/min
Read by machine on 9 November 2026.
Where in Italy
- IRCCS Ospedale Policlinico San MartinoGenoa, ItalyTaking people
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
- Azienda Ospedaliera di PadovaPadova, ItalyTaking people
- Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
- Azienda Ospedaliera Policlinico Universitario Tor VergataRome, ItalyTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
- Humanitas Mirasole S.p.A.Rozzano, ItalyTaking people
- Azienda Sanitaria Universitaria Giuliano IsontinaTrieste, ItalyTaking people
- Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di TorinoTurin, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Azienda Ospedaliera di Padova
- Trial code
- NCT07392229EU 2025-523091-23-00
- Record updated
- 3 April 2026
- Original description
To investigate whether 12 months zanubrutinib treatment lead to an improvement of at least 1 point in at least 2 neurological scales, such as Overall Neuropathy Limitations Scale (ONLS), INCAT disability, INCAT sensory sum scores (ISS), MRC sum score, I-RODS functional score.Read full original descriptionShow less
ZANUBRUTINIB, A SECOND GENERATION BTK INHIBITOR, IN ANTI-MAG ANTIBODY NEUROPATHY: A PHASE II ITALIAN MULTICENTER CLINICAL TRIAL (MAZINGA)
To investigate whether 12 months zanubrutinib treatment lead to an improvement of at least 1 point in at least 2 neurological scales, such as Overall Neuropathy Limitations Scale (ONLS), INCAT disability, INCAT sensory sum scores (ISS), MRC sum score, I-RODS functional score.
Inclusion: ● Age ≥18 years; ● diagnosis of anti-MAG antibody polyneuropathy; ● diagnosis of anti-MAG antibody polyneuropathy; ● IgM monoclonal protein underlying MGUS, Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified; ● Presence of anti MAG antibodies (titer ≥ 7.000 BTU).
Exclusion: ● Previous treatment with BTK inhibitors ● Aggressive non-Hodgkin lymphoma or IgM multiple myeloma ● Evidence of moderate or severe motor nerve axonal damage ● ECOG >3 ● Requiring ongoing therapy with strong or moderate cytochrome P450 3A (CYP3A) inducer. Use of strong/moderate CYP3A inducers within 14 days prior to the first dose of zanubrutinib (see Drug-interaction section). ● creatinine clearance <30mL/min.